Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).

Tumor Hyperinsulinism (Tumor HI)

Rezolute16 participantsStarted Apr 2025

Chicago, Illinois, United States • Bethesda, Maryland, United States • Boston, Massachusetts, United States +10 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism